Compare Moderna, Inc. (MRNA) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Teladoc Health Inc — how do they compare? Moderna, Inc. trades at $140.69 (market cap $58.11B), while Teladoc Health Inc trades at $6.24 (market cap $1.14B). The key difference: Moderna, Inc. is far larger — about 51× Teladoc Health Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | TDOC | |
|---|---|---|
Market Cap | $58.11B | $1.14B |
Sector | Health | Health |
52-Week High | $174.38 | $9.72 |
52-Week Low | $22.36 | $4.47 |
Enterprise Value | $54.26B | $1.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, with a bullish technical signal from moving averages and support at $140. The company reported a net loss of $2.82 billion in 2025, with revenue declining to $1.92 billion, but recent positive phase 3 cancer vaccine trial results have driven investor optimism. Valuation ratios show a P/E of 24.73 and P/S of 25.92, reflecting high growth expectations amid ongoing losses.
The outlook is mixed: breakthrough cancer vaccine progress offers significant upside potential, but persistent negative margins and cash burn pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, indicating skepticism about near-term profitability despite promising pipeline developments.
Teladoc Health (TDOC) trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable near $2.5 billion. Analyst consensus is a Buy rating with a $8.88 price target, but sentiment is mixed due to ongoing losses and recent legal investigations. Cash flow turned negative in 2025 primarily from financing activities.
The outlook hinges on Teladoc's ability to leverage its Integrated Care segment for profitability amid BetterHelp capacity challenges. Upside exists if new CFO leadership improves financial discipline, but risks include persistent losses, competitive pressures, and shareholder litigation. The stock trades below book value, offering potential value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
